Rating Change
Wells Fargo analysts reiterated a Overweight rating on Merck & Co., Inc. (NYSE:MRK) on July 08, 2026.
Rating Change Wells Fargo analysts reiterated a Overweight rating on Merck & Co., Inc. (NYSE:MRK) on July 08, 2026. Market Context Merck & Co., Inc.

Wells Fargo analysts reiterated a Overweight rating on Merck & Co., Inc. (NYSE:MRK) on July 08, 2026.
Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $125.99 with a market capitalization of $248.8B. The stock has gained 46.9% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | RBC Capital | Outperform | N/A |
| Jul 08, 2026 | Wells Fargo | Overweight | N/A |
| Jul 06, 2026 | Cantor Fitzgerald | Neutral | N/A |
| Jun 30, 2026 | Scotiabank | Sector Outperform | N/A |
| Jun 30, 2026 | B of A Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MRK Stock Page
A Overweight rating from Wells Fargo reflects the analyst's outlook on Merck & Co., Inc. (NYSE:MRK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRK forecast page.
Current market data
NYSE · MRK
$148.08
Down: -$0.07 · -0.05%
Live quote updated
Keep reading